Bladder cancer associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial Proliferation

Abstract

RXRA regulates transcription as part of a heterodimer with 14 other nuclear receptors, including the peroxisome proliferator-activated receptors (PPARs). Analysis from the TCGA raised the possibility that hyperactive PPAR signaling, either due to PPAR gamma gene amplification or RXRA hot-spot mutation (S427F/Y) drives 20-25% of human bladder cancers. Here we characterize mutant RXRA, demonstrating it induces enhancer/promoter activity in the context of RXRA/PPAR heterodimers in human bladder cancer cells. Structure-function studies indicate that the RXRA substitution allosterically regulates the PPAR AF2 domain via an aromatic interaction with the terminal tyrosine found in PPARs. In mouse urothelial organoids, PPAR agonism is sufficient to drive growth-factor independent growth in the context of concurrent tumor suppressor loss. Similarly, mutant RXRA stimulates growth-factor independent growth of Trp53/Kdm6a null bladder organoids. Mutant RXRA driven growth of urothelium is reversible by PPAR inhibition, supporting PPARs as targetable drivers of bladder cancer.

Data availability

The following previously published data sets were used

Article and author information

Author details

  1. Angela M Halstead

    Department of Internal Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Chiraag D Kapadia

    Department of Internal Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Jennifer Bolzenius

    Department of Internal Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Clarence E Chu

    Department of Internal Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Andrew Schriefer

    Genome Technology Access Center, Washington University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Lukas D Wartman

    Department of Internal Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5499-8465
  7. Gregory R Bowman

    Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Vivek K Arora

    Department of Internal Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, United States
    For correspondence
    arorav@wustl.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1694-9109

Funding

Damon Runyon Cancer Research Foundation (Clinical Investigator)

  • Vivek K Arora

Cancer Research Foundation (Young Investigator)

  • Vivek K Arora

National Cancer Institute (T32 CA113275)

  • Angela M Halstead

National Center for Advancing Translational Sciences (UL1TR000448)

  • Vivek K Arora

National Cancer Institute (P30 CA91842)

  • Andrew Schriefer

National Institute of Diabetes and Digestive and Kidney Diseases (U54DK104279)

  • Chiraag D Kapadia

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All mouse experiments were performed in accordance with institutional guidelines and current NIH policies and were approved by the Washington University School of Medicine Institutional Animal Care and Use Committee protocol #20140186.

Copyright

© 2017, Halstead et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,763
    views
  • 455
    downloads
  • 60
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Angela M Halstead
  2. Chiraag D Kapadia
  3. Jennifer Bolzenius
  4. Clarence E Chu
  5. Andrew Schriefer
  6. Lukas D Wartman
  7. Gregory R Bowman
  8. Vivek K Arora
(2017)
Bladder cancer associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial Proliferation
eLife 6:e30862.
https://doi.org/10.7554/eLife.30862

Share this article

https://doi.org/10.7554/eLife.30862

Further reading

    1. Cancer Biology
    Han V Han, Richard Efem ... Richard Z Lin
    Research Article

    Most human pancreatic ductal adenocarcinoma (PDAC) are not infiltrated with cytotoxic T cells and are highly resistant to immunotherapy. Over 90% of PDAC have oncogenic KRAS mutations, and phosphoinositide 3-kinases (PI3Ks) are direct effectors of KRAS. Our previous study demonstrated that ablation of Pik3ca in KPC (KrasG12D; Trp53R172H; Pdx1-Cre) pancreatic cancer cells induced host T cells to infiltrate and completely eliminate the tumors in a syngeneic orthotopic implantation mouse model. Now, we show that implantation of Pik3ca−/− KPC (named αKO) cancer cells induces clonal enrichment of cytotoxic T cells infiltrating the pancreatic tumors. To identify potential molecules that can regulate the activity of these anti-tumor T cells, we conducted an in vivo genome-wide gene-deletion screen using αKO cells implanted in the mouse pancreas. The result shows that deletion of propionyl-CoA carboxylase subunit B gene (Pccb) in αKO cells (named p-αKO) leads to immune evasion, tumor progression, and death of host mice. Surprisingly, p-αKO tumors are still infiltrated with clonally enriched CD8+ T cells but they are inactive against tumor cells. However, blockade of PD-L1/PD1 interaction reactivated these clonally enriched T cells infiltrating p-αKO tumors, leading to slower tumor progression and improve survival of host mice. These results indicate that Pccb can modulate the activity of cytotoxic T cells infiltrating some pancreatic cancers and this understanding may lead to improvement in immunotherapy for this difficult-to-treat cancer.

    1. Cancer Biology
    2. Immunology and Inflammation
    Almudena Mendez-Perez, Andres M Acosta-Moreno ... Esteban Veiga
    Short Report

    In this study, we present a proof-of-concept classical vaccination experiment that validates the in silico identification of tumor neoantigens (TNAs) using a machine learning-based platform called NAP-CNB. Unlike other TNA predictors, NAP-CNB leverages RNA-seq data to consider the relative expression of neoantigens in tumors. Our experiments show the efficacy of NAP-CNB. Predicted TNAs elicited potent antitumor responses in mice following classical vaccination protocols. Notably, optimal antitumor activity was observed when targeting the antigen with higher expression in the tumor, which was not the most immunogenic. Additionally, the vaccination combining different neoantigens resulted in vastly improved responses compared to each one individually, showing the worth of multiantigen-based approaches. These findings validate NAP-CNB as an innovative TNA identification platform and make a substantial contribution to advancing the next generation of personalized immunotherapies.